Evidence map›Paper›PMID 34013383›Full record

ArticleVirchows Archiv : an international journal of pathology2022

Clinicopathologic and molecular characterization of melanomas mutated for CTNNB1 and MAPK.

Bénédicte Oulès, Samia Mourah, Barouyr Baroudjian, Fanélie Jouenne, Julie Delyon, Baptiste Louveau, Aurélia Gruber, Céleste Lebbé, Maxime Battistella

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Oncology letters · 2025
    Article
  3. Article
  4. Review
  5. Wnt Signaling Inhibitors and Their Promising Role in Tumor Treatment.International journal of molecular sciences · 2023
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Bénédicte OulèsDepartment of Dermatology and Centre D'investigation Clinique (CIC), Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010, Paris, France.ORCID http://orcid.org/0000-0001-8269-4306
Samia MourahDepartment of Pharmacology and Tumor Genomics, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010, Paris, France.ORCID http://orcid.org/0000-0002-9283-1068
Barouyr BaroudjianDepartment of Dermatology and Centre D'investigation Clinique (CIC), Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010, Paris, France.ORCID http://orcid.org/0000-0001-8234-6766
Fanélie JouenneDepartment of Pharmacology and Tumor Genomics, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010, Paris, France.ORCID http://orcid.org/0000-0002-6706-7424
Julie DelyonDepartment of Dermatology and Centre D'investigation Clinique (CIC), Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010, Paris, France.ORCID http://orcid.org/0000-0002-4557-3377
Baptiste LouveauDepartment of Pharmacology and Tumor Genomics, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010, Paris, France.ORCID http://orcid.org/0000-0001-5411-3893
Aurélia GruberDepartment of Pharmacology and Tumor Genomics, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010, Paris, France.
Céleste LebbéDepartment of Dermatology and Centre D'investigation Clinique (CIC), Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010, Paris, France.ORCID http://orcid.org/0000-0002-5854-7290
Maxime BattistellaUniversité de Paris, INSERM UMRS 976, 75010, Paris, France. maxime.battistella@aphp.fr.ORCID http://orcid.org/0000-0002-7053-7431
Inserm · FRAssistance Publique – Hôpitaux de Paris · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Wnt/β-catenin signaling plays crucial roles in melanocyte biology and may be implicated in melanoma progression. In this study, we retrospectively examined a real-life cohort of melanomas mutated for β-catenin (CTNNB1), in association or not with a MAPK mutation (of BRAF or NRAS), and analyzed their clinical, histopathological, and molecular characteristics. Our results indicate that, regardless of the presence of a concurrent MAPK mutation, CTNNB1

Indexed as

MelanomaSkin Neoplasmsbeta CateninCutaneous Malignant MelanomaHumansMutationProto-Oncogene Proteins B-rafRetrospective Studiesbeta CateninCTNNB1 protein, humanProto-Oncogene Proteins B-rafBRAF mutationCTNNB1 mutationCutaneous melanomaDeep penetrating nevusNRAS mutation

Identifiers

PMID34013383
OpenAlexW3163433376

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.